search
Back to results

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

Primary Purpose

Huntington Disease

Status
Unknown status
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Far Infrared Radiation
Sponsored by
GAAD Medical Research Institute Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Huntington Disease focused on measuring Akinetic-Rigid Variant of Huntington Disease, Chorea, Chronic Progressive Hereditary (Huntington), Chronic Progressive Hereditary Chorea (Huntington), Huntington Chorea, Huntington Chronic Progressive Hereditary Chorea, Huntington Disease, Akinetic-Rigid Variant, Huntington Disease, Juvenile, Huntington Disease, Juvenile-Onset

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • People with HD

Exclusion Criteria:

  • None

Sites / Locations

  • The Centre for Incurable Diseases

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Outcomes

Primary Outcome Measures

Treatment of people with HD

Secondary Outcome Measures

Rehabilitation of people with HD

Full Information

First Posted
May 6, 2008
Last Updated
January 2, 2009
Sponsor
GAAD Medical Research Institute Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00675077
Brief Title
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Official Title
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Unknown status
Study Start Date
May 2008 (undefined)
Primary Completion Date
May 2010 (Anticipated)
Study Completion Date
June 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
GAAD Medical Research Institute Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.
Detailed Description
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Huntington Disease
Keywords
Akinetic-Rigid Variant of Huntington Disease, Chorea, Chronic Progressive Hereditary (Huntington), Chronic Progressive Hereditary Chorea (Huntington), Huntington Chorea, Huntington Chronic Progressive Hereditary Chorea, Huntington Disease, Akinetic-Rigid Variant, Huntington Disease, Juvenile, Huntington Disease, Juvenile-Onset

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Intervention Type
Radiation
Intervention Name(s)
Far Infrared Radiation
Other Intervention Name(s)
Far Infrared Radiation (5μm to 20μm wavelength)
Intervention Description
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Primary Outcome Measure Information:
Title
Treatment of people with HD
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Rehabilitation of people with HD
Time Frame
2 Years

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: People with HD Exclusion Criteria: None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ken Nedd, M.D.
Organizational Affiliation
GAAD Medical Research Institute Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Centre for Incurable Diseases
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4V 1L5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

We'll reach out to this number within 24 hrs